CHIMERIC ANTIGEN RECEPTOR TO TARGET TROP-2-POSITIVE CANCERS

Embodiments of the disclosure include methods and compositions related to targeting of TROP-2-expressing cells with particular engineered receptors. In specific embodimetns, NK cells are specifically engineered to bind TROP-2 using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the TROP-2-targeting CARs also express a particular suicide gene and/or one or more particular cytokines..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 08. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

REZVANI KATY [VerfasserIn]
ACHARYA SUNIL [VerfasserIn]
MERIC-BERNSTAM FUNDA [VerfasserIn]
UPRETY NADIMA [VerfasserIn]
BASAR RAFET [VerfasserIn]
MARIN COSTA DAVID [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-02-08, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26

Patentnummer:

AU2022306051

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA000331929